The trial’s novel immunotherapy, which adjusts traditional treatment sequences, has reduced recurrence rates in advanced melanoma patients to below 5% while significantly improving survival rates.
52-year-old Matthew Croxford is a living example of its success. He once faced despair due to a golf ball-sized tumor but is now cancer-free with no side effects after participating in the trial.
Researchers explain the therapy works by enhancing long-term immune system activation, targeting residual cancer cells that often trigger relapses. Its low toxicity also helps maintain patients’ quality of life.
This breakthrough could reshape global advanced melanoma treatment, offering a viable solution even for late-stage cases. Experts anticipate its wider use will soon lower melanoma-related deaths in high-risk areas.
